OCON Therapeutics Revenue and Competitors

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. \n\nIn the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs.\n\nOCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. \n\nThe Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. \n\nIn addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications.\n\nOCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.